Compare GILT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GILT | TECX |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | Israel | United States |
| Employees | 1159 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.3M | 618.9M |
| IPO Year | 1997 | 2018 |
| Metric | GILT | TECX |
|---|---|---|
| Price | $7.69 | $19.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $19.20 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 923.6K | 182.1K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.44 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | $42.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.23 | $15.60 |
| 52 Week High | $20.99 | $39.53 |
| Indicator | GILT | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 30.40 |
| Support Level | $7.23 | $16.77 |
| Resistance Level | $10.39 | $22.44 |
| Average True Range (ATR) | 0.31 | 1.08 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 38.96 | 4.51 |
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.